ADMA Biologics: Investors with Over $100K Losses Can Join Securities Fraud Lawsuit
Rosen Law Firm is reminding purchasers of ADMA Biologics securities who sustained losses exceeding $100,000 of the opportunity to lead a securities fraud lawsuit.
Rosen Law Firm, a global investor rights law firm, has alerted purchasers of ADMA Biologics, Inc. (NASDAQ: ADMA) securities about a potential securities fraud lawsuit. The firm is seeking investors who have experienced losses of over $100,000 during the specified class period.
The lawsuit targets alleged securities fraud related to ADMA Biologics' stock between August 9, 2024, and March 25, 2026. Investors meeting the loss threshold and other criteria are being encouraged by the law firm to serve as lead plaintiffs.
Interested parties have a deadline of August 10, 2026, to file motions with the court to be appointed as lead plaintiff. The firm is offering consultations to potential class members.
ADMA Biologics is a biopharmaceutical company focused on the development and commercialization of plasma-derived biologics for the treatment of rare diseases.